{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:17:54Z","timestamp":1761549474092,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007121","name":"Hefei Institutes of Physical Science, Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007121","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003995","name":"Natural Science Foundation of Anhui Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.nano.2020.102283","type":"journal-article","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T03:05:17Z","timestamp":1596769517000},"page":"102283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["An ultra-long circulating nanoparticle for reviving a highly selective BCR-ABL inhibitor in long-term effective and safe treatment of chronic myeloid leukemia"],"prefix":"10.1016","volume":"29","author":[{"given":"Liyi","family":"Fu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengming","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingwang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beilei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huamin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinjun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingsong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nano.2020.102283_bb0005","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s40261-017-0587-z","article-title":"Cost effectiveness of imatinib, dasatinib, and nilotinib as first-line treatment for chronic-phase chronic myeloid leukemia in China","volume":"38","author":"Li","year":"2018","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.nano.2020.102283_bb0010","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"Mechanisms of disease\u2014the biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nano.2020.102283_bb0015","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.nano.2020.102283_bb0020","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Mechanisms of disease-chronic myeloid leukemia-advances in biology and new approaches to treatment","volume":"349","author":"Goldman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nano.2020.102283_bb0025","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1182\/blood.V89.9.3487","article-title":"Delicious poison: arsenic trioxide for the treatment of leukemia","volume":"89","author":"Kwong","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.nano.2020.102283_bb0030","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood.V84.12.4064.bloodjournal84124064","article-title":"Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group [see comments]","volume":"84","author":"Hehlmann","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.nano.2020.102283_bb0035","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2015.36","article-title":"Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV","volume":"29","author":"Kalmanti","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.nano.2020.102283_bb0040","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.nano.2020.102283_bb0045","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1200\/JCO.2003.11.143","article-title":"Practical management of patients with chronic myeloid leukemia receiving imatinib","volume":"21","author":"Deininger","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nano.2020.102283_bb0050","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","article-title":"Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib","volume":"103","author":"Gambacorti-Passerini","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.nano.2020.102283_bb0055","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1055\/s-0038-1624566","article-title":"BCR-ABL tyrosine kinase inhibitors: which mechanism(s) may explain the risk of thrombosis?","volume":"2","author":"Haguet","year":"2018","journal-title":"TH Open"},{"key":"10.1016\/j.nano.2020.102283_bb0060","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/onc.2010.494","article-title":"Tumor-intrinsic and -extrinsic roles of c-kit: mast cells as the primary off-target of tyrosine kinase inhibitors","volume":"30","author":"Pittoni","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.nano.2020.102283_bb0065","doi-asserted-by":"crossref","DOI":"10.1186\/s40959-015-0008-5","article-title":"Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia","volume":"1","author":"Pasvolsky","year":"2015","journal-title":"Cardio-Oncology"},{"key":"10.1016\/j.nano.2020.102283_bb0070","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.3109\/10428194.2012.695779","article-title":"Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia","volume":"53","author":"Steegmann","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.nano.2020.102283_bb0075","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1021\/acs.jmedchem.5b01618","volume":"59","author":"Liang","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.nano.2020.102283_bb0080","doi-asserted-by":"crossref","first-page":"8230","DOI":"10.1073\/pnas.1120508109","article-title":"Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery","volume":"109","author":"Karve","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nano.2020.102283_bb0085","doi-asserted-by":"crossref","first-page":"8230","DOI":"10.1073\/pnas.1120508109","article-title":"Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery","volume":"109","author":"Karve","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nano.2020.102283_bb0090","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/sj.clpt.6100400","article-title":"Nanoparticles in medicine: therapeutic applications and developments","volume":"83","author":"Zhang","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.nano.2020.102283_bb0095","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1182\/blood-2014-09-601674","article-title":"Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.nano.2020.102283_bb0100","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1021\/nn203735b","article-title":"Multidentate catechol-based polyethylene glycol oligomers provide enhanced stability and biocompatibility to iron oxide nanoparticies","volume":"6","author":"Na","year":"2012","journal-title":"ACS Nano"},{"key":"10.1016\/j.nano.2020.102283_bb0105","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"Suk","year":"2016","journal-title":"Adv Drug Del Rev"},{"key":"10.1016\/j.nano.2020.102283_bb0110","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jconrel.2014.06.046","article-title":"PEG \u2014 a versatile conjugating ligand for drugs and drug delivery systems","volume":"192","author":"Kolate","year":"2014","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2020.102283_bb0115","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.biomaterials.2018.07.024","article-title":"Surface modification of polymer nanoparticles with native albumin for enhancing drug delivery to solid tumors","volume":"180","author":"Hyun","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.nano.2020.102283_bb0120","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jconrel.2017.04.036","article-title":"An approach for half-life extension and activity preservation of an anti-diabetic peptide drug based on genetic fusion with an albumin-binding aptide","volume":"256","author":"Kim","year":"2017","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2020.102283_bb0125","doi-asserted-by":"crossref","first-page":"6225","DOI":"10.1002\/smll.201502388","article-title":"Red blood cell membrane as a biomimetic nanocoating for prolonged circulation time and reduced accelerated blood clearance","volume":"11","author":"Rao","year":"2015","journal-title":"Small"},{"key":"10.1016\/j.nano.2020.102283_bb0130","doi-asserted-by":"crossref","first-page":"8838","DOI":"10.1021\/acsnano.7b03003","article-title":"Transformative nanomedicine of an amphiphilic camptothecin prodrug for long circulation and high tumor uptake in cancer therapy","volume":"11","author":"Zhang","year":"2017","journal-title":"ACS Nano"},{"key":"10.1016\/j.nano.2020.102283_bb0135","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2174\/157341310791658991","article-title":"Long-circulating targeted nanoparticles for cancer therapy","volume":"6","author":"Liu","year":"2010","journal-title":"Curr Nanosci"},{"key":"10.1016\/j.nano.2020.102283_bb0140","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1021\/mp800051m","article-title":"Factors affecting the clearance and biodistribution of polymeric nanoparticles","volume":"5","author":"Alexis","year":"2008","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nano.2020.102283_bb0145","doi-asserted-by":"crossref","first-page":"7195","DOI":"10.1021\/acsnano.5b02017","article-title":"The role of micelle size in tumor accumulation, penetration, and treatment","volume":"9","author":"Wang","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.nano.2020.102283_bb0150","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/smll.201201390","article-title":"Physicochemical characteristics of nanoparticles affect circulation, biodistribution, cellular internalization, and trafficking","volume":"9","author":"Duan","year":"2013","journal-title":"Small"},{"key":"10.1016\/j.nano.2020.102283_bb0155","doi-asserted-by":"crossref","first-page":"10130","DOI":"10.1021\/acsnano.8b04947","article-title":"Dense and dynamic polyethylene glycol shells cloak nanoparticles from uptake by liver endothelial cells for long blood circulation","volume":"12","author":"Zhou","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.nano.2020.102283_bb0160","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.1021\/acs.chemrev.5b00589","article-title":"Targeted drug delivery with polymers and magnetic nanoparticles: covalent and noncovalent approaches, release control, and clinical studies","volume":"116","author":"Ulbrich","year":"2016","journal-title":"Chem Rev"},{"key":"10.1016\/j.nano.2020.102283_bb0165","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1021\/acs.nanolett.6b01632","article-title":"Self-assembled redox dual-responsive prodrug-nanosystem formed by single thioether-bridged paclitaxel-fatty acid conjugate for cancer chemotherapy","volume":"16","author":"Luo","year":"2016","journal-title":"Nano Lett"},{"key":"10.1016\/j.nano.2020.102283_bb0170","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.carbpol.2015.10.050","article-title":"pH-sensitive polymeric micelles formed by doxorubicin conjugated prodrugs for co-delivery of doxorubicin and paclitaxel","volume":"137","author":"Ma","year":"2016","journal-title":"Carbohydr Polym"},{"key":"10.1016\/j.nano.2020.102283_bb0175","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1021\/acs.biomac.6b01704","article-title":"Stimuli-responsive polymersomes for biomedical applications","volume":"18","author":"Hu","year":"2017","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.nano.2020.102283_bb0180","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.biotechadv.2013.11.009","article-title":"pH-sensitive nano-systems for drug delivery in cancer therapy","volume":"32","author":"Liu","year":"2014","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.nano.2020.102283_bb0185","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1021\/acs.nanolett.8b00737","article-title":"Disulfide bond-driven oxidation- and reduction-responsive prodrug nanoassemblies for cancer therapy","volume":"18","author":"Sun","year":"2018","journal-title":"Nano Lett"},{"key":"10.1016\/j.nano.2020.102283_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biomaterials.2017.09.003","article-title":"Poly(2-ethyl-2-oxazoline) conjugates with doxorubicin for cancer therapy: in vitro and in vivo evaluation and direct comparison to poly N-(2-hydroxypropyl)methacrylamide analogues","volume":"146","author":"Sedlacek","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.nano.2020.102283_bb0195","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.msec.2017.03.201","article-title":"Schiff base bond-linked polysaccharide-doxorubicin conjugate for upregulated cancer therapy","volume":"76","author":"Feng","year":"2017","journal-title":"Mat Sci Eng C-Mater"},{"key":"10.1016\/j.nano.2020.102283_bb0200","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1039\/c2py20290e","article-title":"Schiff's base as a stimuli-responsive linker in polymer chemistry","volume":"3","author":"Xin","year":"2012","journal-title":"Polym Chem"},{"key":"10.1016\/j.nano.2020.102283_bb0205","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.biomaterials.2015.10.016","article-title":"Synergistic therapeutic effects of Schiffs base cross-linked injectable hydrogels for local co-delivery of metformin and 5-fluorouracil in a mouse colon carcinoma model","volume":"75","author":"Wu","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.nano.2020.102283_bb0210","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1021\/am508291k","article-title":"Galactose targeted pH-responsive copolymer conjugated with near infrared fluorescence probe for imaging of intelligent drug delivery","volume":"7","author":"Fu","year":"2015","journal-title":"ACS Appl Mater Interfaces"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963420301374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963420301374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:12:09Z","timestamp":1761549129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963420301374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":42,"alternative-id":["S1549963420301374"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2020.102283","relation":{},"ISSN":["1549-9634"],"issn-type":[{"type":"print","value":"1549-9634"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An ultra-long circulating nanoparticle for reviving a highly selective BCR-ABL inhibitor in long-term effective and safe treatment of chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2020.102283","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102283"}}